ALLMedicine™ Growth Hormone Deficiency Center
Research & Reviews 947 results
https://doi.org/10.1007/s40618-022-01880-w
Journal of Endocrinological Investigation; Cannavò S, Cappa M et. al.
Aug 13th, 2022 - Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement.|2022|Cannavò S,Cappa M,Ferone D,Isidori AM,Loche S,|
https://clinicaltrials.gov/ct2/show/NCT01909479
Aug 12th, 2022 - This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).
https://doi.org/10.4155/tde-2022-0032
Therapeutic Delivery; Simpson I
Aug 5th, 2022 - This industry update covers the period from January 1 through January 31, 2022, and is based on information sourced from company press releases, scientific literature, patents and news websites. January 2022 saw Janssen and Midatech expand their c...
https://clinicaltrials.gov/ct2/show/NCT02988687
Aug 4th, 2022 - Growth hormone replacement has consistently shown improvements in body composition, exercise capacity, endothelial function, inflammatory biomarkers, bone mineral density, lipoprotein metabolism, and self-reported quality of Life (QOL) in patients...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325485
Disease Markers; Wang P, Jin X et. al.
Jul 30th, 2022 - Growth hormone deficiency (GHD) refers to the complete or partial lack of pituitary growth hormone synthesis and secretion. This study is aimed at investigating the efficacy of vitamin D and recombinant human growth hormone (rhGH) in children with...
Guidelines 1 results
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.
Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...
Drugs 14 results see all →
Clinicaltrials.gov 165 results
https://clinicaltrials.gov/ct2/show/NCT01909479
Aug 12th, 2022 - This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).
https://clinicaltrials.gov/ct2/show/NCT02988687
Aug 4th, 2022 - Growth hormone replacement has consistently shown improvements in body composition, exercise capacity, endothelial function, inflammatory biomarkers, bone mineral density, lipoprotein metabolism, and self-reported quality of Life (QOL) in patients...
https://clinicaltrials.gov/ct2/show/NCT05187377
Jul 26th, 2022 - This study will show that select electrophysiological markers in PMS are relevant to iASD and predictive of treatment response with growth hormone. The long-term goal is to optimize treatment selection in iASD by establishing biological signature(...
https://clinicaltrials.gov/ct2/show/NCT02413138
Jul 25th, 2022 - The trial will consist of three stages: 1) a 30 day Phase 2 PK and PD evaluation of somavaratan, 2) an optional Phase 2 Extension and 3) a 12 month Phase 3 safety and efficacy stage. The study is a randomized, multi-center, open label study. The p...
https://clinicaltrials.gov/ct2/show/NCT03972345
Jul 15th, 2022 - Participants are free to decide if they want to take part in this study or not. The study will be conducted to collect information about the influence of adherence to growth hormone therapy with Norditropin® in children and teenagers in daily prac...
News 76 results
https://www.medscape.com/viewarticle/958043
Sep 2nd, 2021 - The US Food and Drug Administration (FDA) has approved lonapegsomatropin (Skytrofa, Ascendis Pharma), the first weekly subcutaneous injectable growth hormone for children with growth hormone deficiency (GHD). The approval was based on the findings...
https://www.medpagetoday.com/endocrinology/generalendocrinology/92929
Jun 6th, 2021 - The investigational dual GIP and GLP-1 receptor agonist tirzepatide significantly reduced HbA1c levels and induced weight loss in patients with type 2 diabetes compared with insulin glargine in the SURPASS-4 trial, Eli Lilly announced. A randomize...
https://www.medscape.com/viewarticle/947349
Mar 12th, 2021 - Children who have been treated for brain tumors often experience significant weight gain, and new findings suggest that this could be a sign of hypothalamic-pituitary (HP) dysfunction. "We believe that endocrine surveillance should be initiated ea...
https://www.mdedge.com/pediatrics/article/234747/endocrinology/childhood-growth-hormones-raise-risk-adult-cardiovascular
Heidi Splete
Jan 19th, 2021 - Childhood treatment with recombinant human growth hormone was associated with a significantly increased risk of cardiovascular events, based on data from more than 3,000 individuals. “Both excess levels of growth hormone and [growth hormone defici.
https://www.staging.medscape.com/viewarticle/940135
Nov 2nd, 2020 - Endocrine diseases of any type — not just diabetes — can represent a cardiovascular risk and patients with those disorders should be screened for high cholesterol, according to a new clinical practice guideline from the Endocrine Society. "The sim...